EIF4E3 Antibody

What is EIF4E3 and why is it important in cancer research?

EIF4E3 is the third subfamily of eukaryotic translation initiation factor 4E proteins that unexpectedly functions as a tumor suppressor through its cap-binding activity. Unlike eIF4E1 which promotes oncogenic transformation, EIF4E3 represses the expression of targets commonly associated with cancer progression including VEGF, c-Myc, Cyclin D1, and NBS1 .

Its importance in cancer research stems from observations that EIF4E3 levels are reduced 3- to 10-fold in M4/M5 acute myeloid leukemia (AML) patients compared to healthy volunteers, while eIF4E1 is elevated . This pattern suggests that malignancy may develop not only through elevation of oncogenic eIF4E1 but also through concomitant loss of the repressive activity of eIF4E3, making it a potential diagnostic marker and therapeutic target.

How do I select the appropriate EIF4E3 antibody for my research?

When selecting an EIF4E3 antibody, consider:

• The specific epitope region - antibodies targeting different regions may yield varying results. For example, the antibody described in search result targets amino acids 1-118, which encompasses the N-terminal region of EIF4E3.

• Cross-reactivity needs - confirm the antibody's reactivity with your species of interest. The antibody in search result reacts with human EIF4E3 and shows cross-reactivity with mouse and rat.

• Applications required - ensure the antibody is validated for your intended applications. The described antibody is validated for Western Blotting , but if you need it for immunoprecipitation, immunohistochemistry, or other techniques, additional validation may be necessary.

• Clonality considerations - polyclonal antibodies like ABIN6140088 recognize multiple epitopes and may provide stronger signals but potentially lower specificity compared to monoclonal antibodies.

• The specific region of interest - since EIF4E3 function depends on its cap-binding activity involving residues like Cys52 and Trp98 , ensure your antibody doesn't interfere with these sites if studying binding interactions.

What are the differences between EIF4E3 and other eIF4E family members that should inform my experimental design?

Key differences that should inform your experimental design include:

• Cap-binding mechanism: EIF4E3 uses a unique Cys52-Trp98 pair for cap recognition rather than the typical aromatic sandwich found in other family members . When studying cap-binding, be aware that EIF4E3 binds with 10- to 40-fold lower affinity than eIF4E1 in vitro (Kd values of 7.7 μM for m7GDP compared to 0.17 μM for eIF4E1) .

• Binding partners: Unlike eIF4E1, EIF4E3 does not associate with eIF4G in cells and has 40-fold less affinity for eIF4G peptide . This significant difference means that when studying translation complexes, you should not expect to co-immunoprecipitate eIF4G with EIF4E3.

• Subcellular localization: Though both eIF4E1 and EIF4E3 are present in the nucleus and cytoplasm , their relative distributions may differ in various cell types.

• Expression patterns: EIF4E3 has a more restricted expression pattern than eIF4E1, being present in hematopoietic cells (THP-1, KG1a) but absent in fibroblasts and U2OS cells . When designing experiments, select appropriate cell lines where EIF4E3 is naturally expressed or consider overexpression systems.

• Function: EIF4E3 represses expression of targets that eIF4E1 enhances, suggesting they compete for the same transcripts . Design experiments that can distinguish between these opposing functions.

How should I validate the specificity of an EIF4E3 antibody?

To validate EIF4E3 antibody specificity:

• Positive and negative controls: Use cell lines with known EIF4E3 expression profiles. Based on search result , THP-1 and KG1a cells express endogenous EIF4E3 (positive controls), while fibroblasts and U2OS cells do not (negative controls).

• Knockdown/knockout validation: Perform siRNA knockdown or CRISPR-Cas9 knockout of EIF4E3 and confirm reduced antibody signal.

• Overexpression validation: Compare wild-type EIF4E3 overexpression to the non-cap-binding mutant (Trp98Ala) described in search result to confirm specificity.

• Peptide competition: Pre-incubate the antibody with the immunizing peptide (amino acids 1-118 for ABIN6140088) to block specific binding.

• Immunoblotting characterization: Confirm that the antibody detects a protein of the expected molecular weight (~23 kDa for EIF4E3) and compare migration patterns with recombinant protein.

• Cross-reactivity assessment: Test against related family members, particularly eIF4E1, to ensure the antibody doesn't cross-react with these structurally similar proteins.

How can I study the differential cap-binding mechanism of EIF4E3 compared to other eIF4E family members?

To study EIF4E3's unique cap-binding mechanism:

• Site-directed mutagenesis: Create mutants of the key residues identified in search result . The table below shows how different mutations affect cap binding:

*NB = No binding observed

• Cap chromatography: Use m7GTP-Sepharose to compare cap binding of endogenous or overexpressed EIF4E3 versus EIF4E1 in cell lysates. Search result demonstrates that nearly all endogenous EIF4E3 (90+%) was bound to the cap column in KG1a and THP-1 cells.

• Isothermal titration calorimetry (ITC): Compare binding affinities of purified recombinant proteins to various cap analogs (m7GDP, m7GTP, m7GpppG) as performed in search result .

• NMR spectroscopy: Use 1H-15N HSQC titrations to detect even weak associations, as this technique detected EIF4E3 binding to GTP with Kd ~1 mM when ITC could not .

• Structural analysis: Determine crystal or solution structures of EIF4E3 in complex with cap analogs to visualize the atypical binding mechanism involving Cys52 and Trp98 rather than the conventional aromatic sandwich.

• Competition assays: Design in vitro or cellular assays where EIF4E3 and eIF4E1 compete for binding to capped mRNAs to understand the dynamics of their interaction.

What methodologies can I use to investigate the tumor suppressor function of EIF4E3 in different cancer types?

To investigate EIF4E3's tumor suppressor function:

• Expression correlation studies: Compare EIF4E3 and eIF4E1 expression levels in paired normal/tumor samples across cancer types. Search result indicates EIF4E3 is reduced in M4/M5 AML and oral cancers, suggesting this pattern may exist in other malignancies.

• Cap-dependent functional assays: Use wild-type EIF4E3 and the non-cap-binding Trp98Ala mutant to determine if EIF4E3's tumor suppressor function requires cap binding. Search result shows the Trp98Ala mutant failed to repress oncogenic foci formation.

• Anchorage-dependent foci formation assays: Overexpress EIF4E3 in NIH 3T3 or U2OS cells and quantify foci formation. Search result demonstrates that EIF4E3 repressed background foci by approximately threefold.

• Target protein expression analysis: Measure the impact of EIF4E3 overexpression or knockdown on known eIF4E1 targets (VEGF, c-Myc, Cyclin D1, NBS1) by Western blotting. EIF4E3 overexpression decreased expression of these targets in a cap-dependent manner .

• Competitive binding studies: Investigate whether EIF4E3 competes with eIF4E1 for the same mRNA targets using RNA immunoprecipitation followed by sequencing (RIP-seq) or crosslinking immunoprecipitation (CLIP).

• In vivo tumor models: Develop xenograft models with manipulated EIF4E3 expression to assess tumor growth, invasion, and metastasis in vivo.

• Clinical correlation analysis: Analyze patient survival data in relation to EIF4E3 expression levels across different cancer types to determine if low EIF4E3 expression correlates with poor prognosis.

How can I resolve contradictory findings between in vitro and cellular EIF4E3 cap-binding data?

The search results reveal an interesting contradiction: in vitro, EIF4E3 has 10-40 fold lower affinity for the cap than eIF4E1, yet in cells, nearly all endogenous EIF4E3 (90+%) is found in the cap-bound fraction . To resolve this contradiction:

• Investigate potential cellular cofactors: Identify EIF4E3-interacting proteins through immunoprecipitation followed by mass spectrometry. Search result suggests that "binding key partner proteins increases the affinity of eIF4E3 for the cap."

• Assess the role of RNA structure: Examine whether specific 5'-UTR elements modulate EIF4E3 interactions with mRNAs, as search result hypothesizes that "5'-UTR elements may modulate interactions with eIF4E1 and binding factors."

• Perform competitive binding assays: Design experiments where purified EIF4E3 and eIF4E1 compete for cap-binding in the presence or absence of cellular extracts to identify factors that may enhance EIF4E3's cap affinity.

• Study the C-terminal region: Investigate the role of EIF4E3's C-terminus, which "undergoes large changes upon cap binding" and could be involved in additional RNA recognition or protein interactions that stabilize cap binding.

• Examine post-translational modifications: Determine if EIF4E3 undergoes modifications in cells that enhance its cap-binding affinity relative to recombinant protein used in vitro.

• Use proximity labeling techniques: Employ BioID or APEX2 fused to EIF4E3 to identify proteins in its immediate vicinity when bound to capped mRNAs.

• Develop advanced biophysical assays: Use single-molecule fluorescence or surface plasmon resonance to measure binding kinetics in more physiologically relevant conditions.

What strategies can I employ to study EIF4E3's mechanistic role in translational repression?

To investigate EIF4E3's translational repression mechanism:

• Polysome profiling: Compare polysome distribution of known target mRNAs in cells with normal, elevated, or reduced EIF4E3 levels to determine how EIF4E3 affects translation efficiency.

• Ribosome profiling: Perform Ribo-seq in cells with manipulated EIF4E3 expression to obtain genome-wide data on translational impact.

• Reporter assays: Design luciferase reporters with 5' and 3' UTRs from EIF4E3-regulated transcripts to measure the direct impact on translation.

• In vitro translation systems: Reconstitute translation with purified components to determine if EIF4E3 directly inhibits translation initiation or requires additional factors.

• Structure-function studies: Search result notes that EIF4E3 does not associate with eIF4G and has 40-fold less affinity for eIF4G peptide. Investigate whether EIF4E3 sequesters mRNAs away from active translation complexes by competing with eIF4E1 without recruiting the translation machinery.

• mRNP composition analysis: Immunoprecipitate EIF4E3-containing complexes and identify associated proteins and RNAs to determine if EIF4E3 recruits specific translational repressors.

• Single-molecule imaging: Visualize the dynamics of EIF4E3 association with mRNAs in living cells and compare with eIF4E1 to understand competitive interactions.

What are the optimal conditions for using EIF4E3 antibodies in Western blotting?

For optimal Western blotting with EIF4E3 antibodies:

• Sample preparation: Use cell lysis buffers containing phosphatase inhibitors since cap-binding proteins can be phosphorylated. Include RNase in some samples to determine if RNA binding affects antibody recognition.

• Sample selection: Include positive controls (THP-1, KG1a cells) and negative controls (fibroblasts, U2OS cells) based on search result .

• Protein amount: Load 20-50 μg of total protein per lane, with potentially higher amounts needed for cells with low endogenous EIF4E3 expression.

• Gel percentage: Use 12-15% SDS-PAGE gels for optimal resolution of EIF4E3 (~23 kDa).

• Transfer conditions: Use PVDF membranes with higher protein binding capacity and semi-dry transfer systems with 20% methanol for efficient transfer of smaller proteins.

• Blocking optimization: Test both 5% non-fat dry milk and 5% BSA in TBST as blocking agents, as some antibodies perform better with one versus the other.

• Antibody dilution: Start with 1:1000 dilution for the primary antibody (ABIN6140088) and optimize as needed.

• Incubation conditions: Incubate primary antibody overnight at 4°C to maximize specific binding and reduce background.

• Washing stringency: Perform at least 3-4 washes with TBST to reduce non-specific binding.

• Detection system: Use high-sensitivity ECL reagents for low abundance proteins or fluorescent secondary antibodies for more quantitative analysis.

How can I design experiments to differentiate between EIF4E3's nuclear and cytoplasmic functions?

To differentiate between nuclear and cytoplasmic functions of EIF4E3:

• Subcellular fractionation: Perform careful biochemical fractionation to isolate nuclear and cytoplasmic compartments for Western blotting. Search result confirms EIF4E3 is present in both compartments.

• Localization-restricted mutants: Generate EIF4E3 constructs with added nuclear localization signals (NLS) or nuclear export signals (NES) to enrich protein in specific compartments.

• Compartment-specific knockdown: Design nuclear or cytoplasmic-targeted degradation systems (e.g., using TRIM21 or AID systems) to selectively reduce EIF4E3 in one compartment.

• Fluorescence microscopy: Use fluorescently tagged EIF4E3 for live-cell imaging to track its movements between compartments, particularly in response to cellular stresses.

• Proximity labeling: Employ compartment-specific BioID or APEX2 fusions to identify interaction partners unique to nuclear or cytoplasmic EIF4E3.

• RNA-protein interaction mapping: Perform CLIP-seq with nuclear and cytoplasmic fractions to identify compartment-specific EIF4E3-bound transcripts.

• Functional assays: Compare the impact of compartment-restricted EIF4E3 on:

  • mRNA export (nuclear function)

  • Translation efficiency (cytoplasmic function)

  • Target protein expression (endpoint of both processes)

• Response to cellular stress: Monitor EIF4E3 relocalization during stress conditions that affect translation or mRNA export.

What controls should I include when studying EIF4E3 and eIF4E1 competitive interactions?

When studying competitive interactions between EIF4E3 and eIF4E1, include these controls:

• Expression level controls: Verify comparable expression levels of both proteins. Search result indicates that in KG1a and THP-1 cells, "levels of the two proteins were very similar."

• Cap-binding mutants: Include the non-cap-binding mutants (EIF4E3 Trp98Ala and eIF4E1 Trp56Ala/Trp102Ala) as negative controls .

• Target specificity controls: Include non-target mRNAs/proteins (GAPDH, β-Actin, α-Tubulin, Hsp90) that are unaffected by either protein .

• Dose-response experiments: Vary the ratio of EIF4E3:eIF4E1 to determine the threshold at which competition becomes effective.

• Time-course analysis: Include multiple time points to capture dynamic changes in target expression after modulating EIF4E3 or eIF4E1 levels.

• Cell type controls: Compare results between cells with endogenous EIF4E3 expression (THP-1, KG1a) and those without (fibroblasts, U2OS) .

• Physiological relevance controls: Compare findings in normal cells versus cancer cells with altered EIF4E3:eIF4E1 ratios.

• mRNA level controls: Measure both protein and mRNA levels of targets to distinguish translational from transcriptional effects.

• Cap analog competition: Include m7GTP cap analogs to disrupt both proteins' binding to capped mRNAs as a positive control for cap-dependent effects.

How can EIF4E3 antibodies be used to develop potential diagnostic tools for cancer?

EIF4E3 antibodies could serve as diagnostic tools based on several findings from search result :

• Expression ratio analysis: Develop immunohistochemistry or multiplex immunofluorescence assays to measure the EIF4E3:eIF4E1 ratio in tissue samples. Search result indicates EIF4E3 is reduced in M4/M5 AML patients while eIF4E1 is elevated 3-10 fold.

• Prognostic marker development: Create tissue microarray studies correlating EIF4E3 expression with patient outcomes across cancer types.

• Liquid biopsy applications: Develop methods to detect EIF4E3 protein or its encoding mRNA in circulating tumor cells or extracellular vesicles.

• Multi-parameter flow cytometry: Design antibody panels including EIF4E3 and eIF4E1 for analyzing hematological malignancies since EIF4E3 is expressed in hematopoietic cells .

• Cap-binding activity assays: Create diagnostic tests based on reduced cap-binding competition in cancer cells with low EIF4E3 levels.

• Target protein signature: Develop multiplex assays measuring multiple EIF4E3/eIF4E1 targets (VEGF, c-Myc, Cyclin D1, NBS1) as a functional readout of the pathway's activation state.

• Companion diagnostics: Incorporate EIF4E3 testing into diagnostic algorithms for cancers where translation dysregulation is a known factor, especially if therapeutics targeting this pathway are developed.

• Early detection research: Investigate whether EIF4E3 downregulation is an early event in carcinogenesis that could be detected before clinical presentation.

What methodological approaches are most effective for studying EIF4E3's role in specific cancer subtypes?

For studying EIF4E3 in specific cancer subtypes:

• Cancer cell line panel screening: Systematically assess EIF4E3 expression across cell line panels representing diverse cancer types to identify those with altered expression.

• Patient sample analysis: Perform immunohistochemistry on tissue microarrays from specific cancer subtypes. Search result suggests focusing on AML (particularly M4/M5 subtypes) and oral cancers where EIF4E3 loss has been documented.

• TCGA/ICGC data mining: Analyze publicly available genomic data to identify cancer types with EIF4E3 alterations (mutations, deletions, expression changes).

• Genetically engineered mouse models: Develop tissue-specific EIF4E3 knockout models to study its role in cancer initiation and progression in specific tissues.

• Patient-derived xenograft models: Establish PDX models from tumors with varying EIF4E3 levels to study functional consequences in a more clinically relevant context.

• 3D organoid cultures: Develop organoid systems from normal and cancer tissues to study EIF4E3's role in a physiologically relevant microenvironment.

• Single-cell analysis: Perform single-cell RNA-seq or protein analysis to identify heterogeneity in EIF4E3 expression within tumors and correlate with stemness or differentiation markers.

• Therapeutic response correlation: Investigate whether EIF4E3 expression levels correlate with response to specific therapies, particularly those targeting translation initiation.